login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
RESVERLOGIX CORP (RVX.CA) Stock News
Canada
- TSX:RVX -
CA76128M1086
-
Common Stock
0.105
CAD
0 (0%)
Last: 10/21/2025, 7:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RVX.CA Latest News, Press Relases and Analysis
All
Press Releases
3 years ago - By: Seeking Alpha
Resverlogix extends debenture maturity by one year (RVX:CA)
3 years ago - By: InvestmentPitch Media and Resverlogix Corp.
- Mentions:
OTC
InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions
3 years ago - By: Resverlogix Corp
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
3 years ago - By: Resverlogix Corp
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
3 years ago - By: Resverlogix Corp
Resverlogix Announces Appointment of New Chief Scientific Officer
3 years ago - By: Resverlogix Corp
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
3 years ago - By: Resverlogix Corp
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
3 years ago - By: Resverlogix Corp
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
4 years ago - By: Resverlogix Corp
Resverlogix Announces One-Year Extension of Debenture
4 years ago - By: Resverlogix Corp
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
4 years ago - By: The Market Herald
- Mentions:
BABY.CA
The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and Resverlogix
4 years ago - By: Resverlogix Corp
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
4 years ago - By: Resverlogix Corp
Resverlogix 宣佈在加拿大開發具有前景的 2019 冠狀病毒病治療的第 2b 期測試開始患者招募和給藥
4 years ago - By: Resverlogix Corp
Resverlogix宣布在加拿大开发的一种有前景的新冠肺炎药物的2b期临床试验中开始患者招募和给药
4 years ago - By: Resverlogix Corp
Resverlogix annonce le début du recrutement et du dosage des patients pour un essai de phase 2b d’un traitement prometteur contre la COVID-19 développé au Canada
4 years ago - By: Resverlogix Corp
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
4 years ago - By: Resverlogix Corp
Resverlogix Announces Corporate Update Webcast and Conference Call
4 years ago - By: Resverlogix Corp
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
4 years ago - By: Resverlogix Corp
Resverlogix与阿拉伯-非洲经济最高委员会签订合作协议,以支持为新冠肺炎患者开发Apabetalone
4 years ago - By: Resverlogix Corp
Resverlogix 與阿拉伯非洲經濟最高委員會達成合作協議,以支援為 2019 冠狀病毒病患者開發 Apabetalone
4 years ago - By: Resverlogix Corp
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
4 years ago - By: Resverlogix Corp
Resverlogix to Participate in Leading Scientific Conferences
4 years ago - By: Resverlogix Corp
Resverlogix to Present at Upcoming Conferences
4 years ago - By: Resverlogix Corp
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Please enable JavaScript to continue using this application.